| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 20,158 | 75,603 | 42,633 | 20,784 |
| Marketable securities | 226,170 | 187,293 | 139,774 | 154,700 |
| Prepaid expenses and other current assets | 6,636 | 5,021 | 2,520 | 1,355 |
| Total current assets | 252,964 | 267,917 | 184,927 | 176,839 |
| Property and equipment, net | 1,057 | 830 | 880 | 856 |
| Other long-term assets | 312 | 256 | 266 | 186 |
| Operating lease right-of-use assets | 7,016 | 7,639 | 4,774 | 5,007 |
| Total assets | 261,349 | 276,642 | 190,847 | 182,888 |
| Accounts payable | 1,495 | 1,016 | 786 | 2,001 |
| Accrued expenses | 2,859 | 6,387 | 4,098 | 3,747 |
| Current portion of operating lease liabilities | 2,303 | 2,341 | 1,477 | 1,466 |
| Total current liabilities | 6,657 | 9,744 | 6,361 | 7,214 |
| Operating lease liabilities, net of current portion | 4,651 | 5,909 | 4,016 | 4,284 |
| Total liabilities | 11,308 | 15,653 | 10,377 | 11,498 |
| Common stock-Common Class A | 32 | 31 | 23 | 19 |
| Common stock-Common Class B | 5 | 6 | 6 | 7 |
| Additional paid-in-capital | 442,093 | 438,072 | 342,400 | 320,649 |
| Accumulated deficit | -191,836 | -177,380 | -162,224 | -149,432 |
| Accumulated other comprehensive income (loss) | -253 | 260 | 265 | 147 |
| Total stockholders' equity | 250,041 | 260,989 | 180,470 | 171,390 |
| Total liabilities and stockholders' equity | 261,349 | 276,642 | 190,847 | 182,888 |
Contineum Therapeutics, Inc. (CTNM)
Contineum Therapeutics, Inc. (CTNM)